Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Not so exclusive: Co-mutations in JAK2, MPL and CALR define distinct hematologic and clonal signatures

Ekrem Turk, Fernando Bustamante, Fatima Tuz Zahra, Yu-Han Chen, Rory Shallis, Onyee Chan, Samuel Reynolds, Alison Walker, Ling Zhang, Seongseok Yun, Jeffrey Lancet, David Sallman, Rami Komrokji, Jinming Song, Eric Padron, Gabriela Hobbs, Andrew Kuykendall, Zhuoer Xie

Blood (2025) 146 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2025-3815

Published: 2025

Journal Articles

Mapping out the impact of MAP kinase in primary myelofibrosis

Samuel Reynolds, Andrew Kuykendall, David Sallman, Gary Reuther, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Alison Walker, Onyee Chan, Seongseok Yun, Eric Padron, Rory Shallis, Jeffrey Lancet, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3812.

https://doi.org/10.1182/blood-2025-3812

Published: 2025

Journal Articles

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Blood (2025) 146 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2025-1726

Published: 2025

Journal Articles

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Kendra Sweet, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3856.

https://doi.org/10.1182/blood-2025-3856

Published: 2025

Journal Articles

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

Abigail Huetteman, Najla Al Ali, David Sallman, Eric Padron, Andrew Kuykendall, Onyee Chan, Zhuoer Xie, Alison Walker, Seongseok Yun, Samuel Reynolds, Kendra Sweet, Rami Komrokji, Jeffrey Lancet

Blood (2025) 146 (Supplement 1): 3853.

https://doi.org/10.1182/blood-2025-3853

Published: 2025

Journal Articles

IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies

Rami Komrokji, Amin Azem, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Samuel Reynolds, Seongseok Yun, Alison Walker, Kendra Sweet, Andrew Kuykendall, Jeffrey Lancet, Eric Padron, David Sallman

Blood (2025) 146 (Supplement 1): 3851.

https://doi.org/10.1182/blood-2025-3851

Published: 2025

Journal Articles

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

Rami Komrokji, Najla Al Ali, Zena Komrokji, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Kendra Sweet, Jeffrey Lancet, Eric Padron, David Sallman

Blood (2025) 146 (Supplement 1): 2072.

https://doi.org/10.1182/blood-2025-2072

Published: 2025

Journal Articles

Racial disparities in genomic alterations and survival outcomes in Acute Myeloid Leukemia (AML)

Utsav Joshi, Fatima Tuz Zahra, Pujan Patel, Najla Al Ali, Zachary Thompson, Nagehan Pakasticali, Jinming Song, Rory Shallis, Zhuoer Xie, Seongseok Yun, Andrew Kuykendall, Eric Padron, Alison Walker, David Sallman, Rami Komrokji, Jeffrey Lancet, Mohammad Hussaini, Onyee Chan

Blood (2025) 146 (Supplement 1): 4630.

https://doi.org/10.1182/blood-2025-4630

Published: 2025

Journal Articles

Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)

Fatima Tuz Zahra, Ekrem Turk, Najla Al Ali, Sean Haney, Dimitrios Drekolias, Nicole Vincelette, Jinming Song, Samuel Reynolds, Rory Shallis, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Eric Padron, Alison Walker, David Sallman, Rami Komrokji, Jeffrey Lancet, Seongseok Yun, Onyee Chan

Blood (2025) 146 (Supplement 1): 291.

https://doi.org/10.1182/blood-2025-291

Published: 2025

Journal Articles

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Omar Alzarkali, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2025-3393

Published: 2025

Journal Articles

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Blood (2025) 146 (Supplement 1): 930.

https://doi.org/10.1182/blood-2025-930

Published: 2025

Journal Articles

Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes

Julie Braish, Najla Al Ali, Zena Komrokji, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 240.

https://doi.org/10.1182/blood-2025-240

Published: 2025

Journal Articles

Machine learning using bayesian networks to predict response in patients with newly diagnosed Acute Myeloid Leukemia

Onyee Chan, Najla Al Ali, Seongseok Yun, David Sallman, Eric Padron, Alison Walker, Rami Komrokji, Gilmer Valdes, Jeffrey Lancet, Issam El Naqa, Yi Luo

Blood (2025) 146 (Supplement 1): 4357.

https://doi.org/10.1182/blood-2025-4357

Published: 2025

Journal Articles

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Onyee Chan, Kendra Sweet, Chetasi Talati, Fatima Tuz Zahra, Lisa Nardelli, Jatinder Lamba, Jongphil Kim, Jinming Song, Samuel Reynolds, Rory Shallis, Zhuoer Xie, Seongseok Yun, Andrew Kuykendall, Eric Padron, Alison Walker, Rami Komrokji, Jeffrey Lancet, David Sallman

Blood (2025) 146 (Supplement 1): 5216.

https://doi.org/10.1182/blood-2025-5216

Published: 2025

Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Blood (2025) 146 (Supplement 1): 453.

https://doi.org/10.1182/blood-2025-453

Published: 2025

Journal Articles

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Blood (2025) 146 (Supplement 1): 5278.

https://doi.org/10.1182/blood-2025-5278

Published: 2025

Journal Articles

High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax - Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes

Jeremy V. DiGennaro, Dimitrios Drekolias, Najla H. Al Ali, Onyee Chan, Seongseok Yun, Alison R. Walker, Zhuoer Xie, Eric Padron, Jeffrey E Lancet, Rami S. Komrokji, David Sallman

Blood (2024) 144 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2024-208927

Published: 2024

Journal Articles

The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS

Ziad Abuhelwa, Najla H. Al Ali, Zhuoer Xie, Onyee Chan, Seongseok Yun, Andrew T. Kuykendall, Alison R. Walker, Jeffrey E Lancet, Eric Padron, David Sallman, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 4589.

https://doi.org/10.1182/blood-2024-204064

Published: 2024

Journal Articles

IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)

Rami S. Komrokji, Najla H. Al Ali, Zhuoer Xie, Zena Komrokji, Joseph E. Jabbour, Onyee Chan, Seongseok Yun, Andrew T. Kuykendall, Alison R. Walker, Jeffrey E Lancet, Eric Padron, David Sallman

Blood (2024) 144 (Supplement 1): 3228.

https://doi.org/10.1182/blood-2024-204167

Published: 2024

Journal Articles

Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas

Fatima Tuz Zahra, Faustine Ong, Moazzam Shahzad, Onyee Chan, Najla H. Al Ali, Jeffrey E Lancet, Alison R. Walker, David Sallman, Rami S. Komrokji, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Zhuoer Xie

Blood (2024) 144 (Supplement 1): 5190.

https://doi.org/10.1182/blood-2024-211740

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Not so exclusive: Co-mutations in JAK2, MPL and CALR define distinct hematologic and clonal signatures

Mapping out the impact of MAP kinase in primary myelofibrosis

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

Racial disparities in genomic alterations and survival outcomes in Acute Myeloid Leukemia (AML)

Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes

Machine learning using bayesian networks to predict response in patients with newly diagnosed Acute Myeloid Leukemia

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax - Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes

The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS

IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)

Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only